Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track HELP with free AI briefings, catalyst countdowns, and dilution alerts.

HELP · Cybin D/B/A Helus Pharma

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$166.4M Cash on Hand

14.2mo Cash Runway

0% Short Interest

$39.77 Analyst Target (10)

Follow HELP by email Get an email when HELP pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about HELP, unsubscribe in one click. Privacy

📣 What HELP Says Is Next

Q4 2026 · “Enrollment is complete in APPROACH, with topline data expected in Q4 2026, while enrollment continues in EMBRACE, the second pivotal study in the Phase 3 PARADIGM program.”
Company press release, Aug 3, 2026 · SEC filing
fourth quarter of 2026 · “The Company intends to use the net proceeds from the Offering to progress the Company's HLP003 for major depressive disorder with Phase 3 APPROACH data expected in the fourth quarter of 2026, HLP004 for generalized anxiety disorder, and HLP005 programs, and for working capital and general corporate purposes.”
Company press release, Jul 16, 2026 · SEC filing
fourth quarter of 2026 · “"This milestone underscores the execution of our clinical program and brings us closer to the anticipated topline data readout in the fourth quarter of 2026.”
Company press release, Jun 25, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

Jun 2027 · Phase 3 · Recruiting · A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Registry primary completion date, not a results date
Jun 2028 · Phase 3 · Enrolling · Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND
Registry primary completion date, not a results date
Sep 2026 · Phase 3 · Active Trial · "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Registry date passed, readout not confirmed

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
CYB003	Major Depressive Disorder (MDD)	Phase 3 · NCT06793397	Recruiting
CYB004	Generalized Anxiety Disorder	Phase 2 · NCT06051721	Completed
Psilocybine	Depression	Phase 2 · NCT05594667	Withdrawn

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

HELP holds $166.4M in cash and short-term investments and burns about $35.2M/quarter from operations, an estimated runway of 14.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 18 · Low

Cash runway 14 months +18

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HELP files for a raise →

👥 Who Owns HELP

Insiders 42.5% Other 5%+ holders 23.7% Institutions 33.8% Public and other holders 0%

Holder	Type	Shares	% of shares	As of
Venrock Healthcare Capital Partners III,	5%+ holder (13G)	5,111,412	23.66%	2025-10-31
Eric H. L. So Executive Chair, Director	Insider	4,518,630	20.92%	2026-09-08
Paul Glavine Chief Growth Officer	Insider	4,502,193	20.84%	2026-09-08
Venrock Adviser, LLC	Institution (13F)	3,851,654	17.83%	2026-06-30
Adage Capital Management, L.P.	Institution (13G, 5%+)	3,289,250	15.23%	2026-06-30
Orbimed Advisors LLC.	Institution (13F)	3,271,400	15.14%	2026-06-30
Adage Capital Partners GP L.L.C.	Institution (13F)	3,060,000	14.17%	2026-06-30
Millennium Management LLC	Institution (13G, 5%+)	2,829,893	13.10%	2026-04-17
Rosalind Advisors, Inc.	Institution (13F)	1,956,814	9.06%	2026-06-30
Sphera Funds Management Ltd.	Institution (13F)	1,620,753	7.50%	2026-06-30
Acorn Capital Advisors, LLC	Institution (13F)	1,540,266	7.13%	2026-06-30
DCF Advisers, LLC	Institution (13F)	1,434,988	6.64%	2026-06-30

Share count 21,601,208 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full HELP picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HELP and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z